fluasterone
Selected indexed studies
- Solubilization of fluasterone. (J Pharm Sci, 1999) [PMID:10514340]
- Identification of [14C]fluasterone metabolites in urine and feces collected from dogs after subcutaneous and oral administration of [14C]fluasterone. (Drug Metab Dispos, 2009) [PMID:19196848]
- Solubilization of Fluasterone in cosolvent/cyclodextrin combinations. (Int J Pharm, 2003) [PMID:12972333]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Solubilization of fluasterone. (1999) pubmed
- Identification of [14C]fluasterone metabolites in urine and feces collected from dogs after subcutaneous and oral administration of [14C]fluasterone. (2009) pubmed
- Solubilization of Fluasterone in cosolvent/cyclodextrin combinations. (2003) pubmed
- Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one. (2002) pubmed
- Therapeutic potential of enzymes, neurosteroids, and synthetic steroids in neurodegenerative disorders: A critical review. (2025) pubmed
- Chemoprevention of rat prostate carcinogenesis by dietary 16alpha-fluoro-5-androsten-17-one (fluasterone), a minimally androgenic analog of dehydroepiandrosterone. (2007) pubmed
- Pharmacokinetic and tissue distribution study of [14C]fluasterone in male Beagle dogs following intravenous, oral and subcutaneous dosing routes. (2010) pubmed
- A synthetic androstene analogue inhibits collagen-induced arthritis in the mouse. (2004) pubmed
- New agents for cancer chemoprevention. (1996) pubmed
- Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: therapeutic implications for multiple sclerosis. (2004) pubmed